At least 10 biotechs and pharmas are slated to report earnings this week. Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is expected to post a nearly 3x increase in 2Q14 EPS on a 42% jump in revenues to $648 million. The large-cap biotech markets ophthalmic drug Eylea aflibercept.

Quarterly EPS for Jazz Pharmaceuticals plc (NASDAQ:JAZZ) and Ligand Pharmaceuticals Inc.